Organon & Co

The FDA has accepted a supplemental application from Organon to extend the duration of use for MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. The product sits within Organon's women's health portfolio, which anchors much of the company's current narrative. Organon's share price has had a quiet week but a strong year, with an 88.95% year to date share price return contrasted against a 30.48% total shareholder return over the past 12 months and weaker multi year outcomes. Against Organon's last close of $13.68, the most followed valuation work points to a fair value of $11.25, while the stock trades on a P/E of 17.2x versus a peer average of 20.7x and a fair ratio of 31x.

The US Food and Drug Administration has accepted for review a supplemental New Drug Application from Sebela Women's Health for MIUDELLA, the hormone-free copper intrauterine system, seeking to extend its approved duration of use from 3 to 6 years, Organon announced. Organon, which in June of 2026 completed an agreement to exclusively license global rights to MIUDELLA, said a Prescription Drug User Fee Act action on the application is expected in the second quarter of calendar year 2027. MIUDELLA is currently indicated for the prevention of pregnancy in females of reproductive potential for up to 3 years and is anticipated to be commercially available in late 2026. The product was investigated in three US clinical trials in 1,904 women aged 17 to 45 years; in the Phase 3 efficacy cohort of women aged 17 to 35 years, the first-year Pearl Index was 0.94 and the cumulative 3-year Pearl Index was 1.05, with an overall placement success rate of about 99 percent. Juan Camilo Arjona Ferreira, Head of Research and Development and Chief Medical Officer at Organon, called the acceptance an important milestone, and Kelly Culwell, Chief Medical Officer and Head of Research and Development at Sebela Women's Health, noted that more than 1,900 women participated in Miudella's clinical trials.

Organon announced that its Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026.

Healthcare M&A deal volume fell in the second quarter of 2026, with 459 publicly announced transactions, down from 553 in Q1:26 and a 23% decline from 503 deals in Q2:25, according to LevinPro HC data. Disclosed spending climbed to $95.3 billion across 78 transactions, nearly tripling the $28.7 billion recorded in Q2:25 and outpacing Q1:26’s $74.7 billion, driven by 21 mega-deals exceeding $1 billion. Physician Medical Group led activity with 106 deals, while eHealth was the most active healthcare technology sector with 58 deals. Private equity deal volume held steady at 151 transactions, increasing its market share to 33% from 27% in Q1:26. The largest deal was Sun Pharmaceutical Industries’ $11.75 billion acquisition of Organon & Co., followed by Merck’s $11.3 billion purchase of Bio-Techne Corporation.

Organon presented a post hoc analysis of pooled Phase 3 data showing that VTAMA cream demonstrated early and consistent improvements in atopic dermatitis across pediatric age groups and adults. The findings, from the ADORING 1 and ADORING 2 trials involving 813 patients with moderate to severe disease, were stratified into four age subsets: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Therapeutic responses measured by vIGA-AD and EASI75 emerged as early as week 2 and continued through week 8, with vIGA-AD response rates at week 8 reaching 56.3% versus 11.8% for vehicle in the youngest group and 38.0% versus 18.1% in adults. VTAMA cream is the first and only aryl hydrocarbon receptor agonist approved for both atopic dermatitis in patients 2 years and older and plaque psoriasis in adults.

Organon shareholders approved the company's proposed merger with Sun Pharmaceutical Holdings USA at a virtual special meeting, clearing a major step in the deal. Under the agreement, Sun Pharma's merger subsidiary will combine with Organon, with Organon surviving as a wholly owned subsidiary of Sun Pharma USA. Shareholders also gave non-binding advisory approval to possible merger-related compensation for Organon's named executive officers. Final certified voting results will be filed with the SEC in a Form 8-K.

Organon has completed a global licensing agreement with Sebela Pharmaceuticals for exclusive rights to MIUDELLA, a hormone-free copper intrauterine device approved by the U.S. FDA in February 2025. MIUDELLA is the first hormone-free copper IUD launched in the U.S. in more than four decades, designed to prevent pregnancy for up to three years with 99% effectiveness. The device features SLIMSERT technology with a flexible frame and a preloaded insertion system using a 3.7mm tapered tube, and is expected to become commercially available in late 2026. Separately, Organon expanded its partnership with Samsung Bioepis, gaining exclusive commercialization rights in Canada for Pyzchiva, a biosimilar referencing Stelara, intended for multiple inflammatory conditions and expected to launch in 2026.

Organon Canada and Shanghai Henlius Biotech have launched BILDYOS and TUZEMTY, biosimilars to PROLIA and XGEVA respectively, in Canada for all indications of the reference products. The two denosumab injection treatments address osteoporosis and bone events associated with cancer, expanding Organon's Canadian biosimilars portfolio to eight products across five therapeutic areas. Dominic Bégin, President and Managing Director at Organon Canada, said the approvals represent an important step toward broadening access to bone-care treatments, noting that osteoporosis affects 2.3 million Canadians. The launch follows a 2022 license and supply agreement granting Organon exclusive commercialization rights to several Henlius biosimilars outside of China.

Organon has completed a global licensing agreement with Sebela Pharmaceuticals for exclusive rights to MIUDELLA, a hormone-free copper intrauterine device. Approved by the US FDA in February 2025, MIUDELLA is the first hormone-free copper IUD introduced in the US in over 40 years and is 99% effective for pregnancy prevention for up to three years. The device features a proprietary flexible frame and a preloaded inserter with a 3.7mm diameter tube. Commercial availability is anticipated in late 2026, with distribution restricted through a Risk Evaluation and Mitigation Strategy program to ensure proper insertion training. The deal strengthens Organon's contraception portfolio and expands long-acting reversible options for women.

Biopharma executives' confidence in the industry has reached its highest point in four years, with 55% of surveyed professionals feeling optimistic or very optimistic about growth over the next 12 months, up from 46% in 2023, according to GlobalData's State of the Biopharmaceutical Industry 2026 mid-year update. The survey of 157 pharmaceutical professionals found that 69% of respondents highlighted US tariffs and government actions as the biggest policy concern, a figure that rose to 78% among European respondents. Deal activity has surged, with first-quarter 2026 M&A deal value rising 71% year over year and life sciences and pharma deals surpassing $65 billion, the strongest quarter since 2020. Notable transactions include Eli Lilly's acquisition of 10 companies this year, led by a $7.8 billion deal for Centessa, while the second quarter saw Sun Pharma's $11.75 billion takeover of Organon and GSK's $10.6 billion acquisition of Nuvalent. The IPO market has also resurged, with activity up 210%, and Parabilis Medicines set a new biotech IPO record with a $670 million Nasdaq listing just two months after Kailera Therapeutics raised $625 million.

Organon and Samsung Bioepis have expanded their development and commercialization agreement, giving Organon exclusive commercial rights in Canada to PYZCHIVA, Samsung Bioepis's biosimilar referencing STELARA. The amended deal deepens their collaboration to six biosimilars in Canada across immunology, oncology, and dermatology, adding PYZCHIVA to a portfolio that already includes HADLIMA, BRENZYS, RENFLEXIS, AYBINTIO, and ONTRUZANT. Samsung Bioepis retains full development, manufacturing, and regulatory responsibilities, while Organon will launch the product in Canada in 2026. PYZCHIVA is indicated for adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis.

PwC reports that US pharma and life sciences deal value surpassed $65 billion in the first quarter of 2026, the strongest quarter since pandemic-related highs in 2020. The surge is driven by the largest patent cliff in industry history, with more than $300 billion in branded pharma revenue exposed, forcing companies to pursue acquisitions in areas like GLP-1 receptor agonists, RNA therapeutics, and antibody-drug conjugates. Eli Lilly has been the most active buyer, purchasing 10 companies this year including a $7.8 billion deal for Centessa. The momentum continued into the second quarter with Sun Pharma's $11.75 billion takeover of Organon and GSK's $10.6 billion acquisition of Nuvalent. PwC expects M&A to remain strong through year-end as large-cap pharma fills loss-of-exclusivity gaps, while a resurgent IPO market saw Parabilis Medicines raise a record $670 million in the largest biotech IPO ever.